• KOL
  • arrow_forward_ios Arthritis
  • arrow_forward_ios Arthritis Kols
  • Paul Emery

    Paul Emery

    Rheumatoid Arthritis  |  Ankylosing Spondylitis |  Radiographic Progression

    Paul Emery

    • Paul Emery: Influence Statistics
    • See prominent publications
    • Tools

     

    Prominent publications by Paul Emery

    Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-


    [ PUBLICATION ]
    KOL Index score: 28323

    BACKGROUND: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. The Oral Rheumatoid Arthritis triaL (ORAL) Strategy aimed to assess the comparative efficacy of tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate for the treatment of rheumatoid arthritis in patients with a previous inadequate response to methotrexate.

    METHODS: ORAL Strategy was a 1 year, double-blind, phase 3b/4, head-to-head, non-inferiority, ...

    Also Ranks for: Tofacitinib Monotherapy |  rheumatoid arthritis |  methotrexate patients |  combination therapy |  oral strategy

    Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study


    [ PUBLICATION ]
    KOL Index score: 22837

    BACKGROUND: Upadacitinib, an oral Janus kinase (JAK)1-selective inhibitor, showed efficacy in combination with stable background conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) in patients with rheumatoid arthritis who had an inadequate response to DMARDs. We aimed to evaluate the safety and efficacy of upadacitinib monotherapy after switching from methotrexate versus continuing methotrexate in patients with inadequate response to methotrexate.

    METHODS: ...

    Also Ranks for: Inadequate Response |  rheumatoid arthritis |  upadacitinib 15 |  week patients |  3 study

    Significant improvement in synovitis, osteitis, and bone erosion following golimumab and methotrexate combination therapy as compared with methotrexate alone: A magnetic resonance imaging study of 318


    [ PUBLICATION ]
    KOL Index score: 21805

    OBJECTIVE: To evaluate the effects of golimumab on inflammation/structural damage detected by magnetic resonance imaging (MRI) in patients with rheumatoid arthritis (RA).

    METHODS: Methotrexate (MTX)-naive RA patients (n = 637) were randomized to placebo plus MTX, golimumab 100 mg plus placebo, golimumab 50 mg plus MTX, or golimumab 100 mg plus MTX (subcutaneous golimumab every 4 weeks). Of these, 318 patients participated in an MRI substudy. MRIs (contrast-enhanced; 1.5T) of the wrist ...

    Also Ranks for: Bone Erosion |  methotrexate combination therapy |  magnetic resonance |  golimumab mtx |  arthritis patients

    Adjustment of therapy in rheumatoid arthritis on the basis of achievement of stable low disease activity with adalimumab plus methotrexate or methotrexate alone: the randomised controlled OPTIMA trial


    [ PUBLICATION ]
    KOL Index score: 21052

    BACKGROUND: Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus methotrexate or methotrexate alone are unclear. The OPTIMA trial assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining (or not) stable low disease activity with adalimumab plus methotrexate or methotrexate monotherapy.

    METHODS: This trial was done at 161 sites worldwide. ...

    Also Ranks for: Methotrexate Patients |  low disease |  rheumatoid arthritis |  primary endpoint |  activity adalimumab

    Rituximab for rheumatoid arthritis refractory to anti–tumor necrosis factor therapy: Results of a multicenter, randomized, double‐blind, placebo‐controlled, phase III trial evaluating primary efficacy


    [ PUBLICATION ]
    KOL Index score: 19826

    OBJECTIVE: To determine the efficacy and safety of treatment with rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to anti-tumor necrosis factor (anti-TNF) therapies and to explore the pharmacokinetics and pharmacodynamics of rituximab in this population.

    METHODS: We evaluated primary efficacy and safety at 24 weeks in patients enrolled in the Randomized Evaluation of Long-Term Efficacy of Rituximab in RA (REFLEX) Trial, a ...

    Also Ranks for: 24 Weeks |  primary efficacy |  rituximab monoclonal antibodies |  rheumatoid arthritis refractory |  tumor necrosis

    Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naïve with active rheumatoid arthritis and an inadequate resp


    [ PUBLICATION ]
    KOL Index score: 19010

    OBJECTIVES: This phase III study evaluated the efficacy and safety of rituximab plus methotrexate (MTX) in patients with active rheumatoid arthritis (RA) who had an inadequate response to MTX and who were naïve to prior biological treatment.

    METHODS: Patients with active disease on stable MTX (10-25 mg/week) were randomised to rituximab 2 x 500 mg (n=168), rituximab 2 x 1000 mg (n=172), or placebo (n=172). From week 24, patients not in remission (Disease Activity Score (28 joints) > or ...

    Also Ranks for: Inadequate Response |  active rheumatoid arthritis |  rituximab patients |  monoclonal antibodies |  efficacy safety

    Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial


    [ PUBLICATION ]
    KOL Index score: 18929

    BACKGROUND: Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha (TNFalpha) is efficacious in relief of signs and symptoms. We therefore investigated whether infliximab, a chimeric human-mouse anti-TNFalpha monoclonal antibody would provide additional clinical benefit to patients who had active rheumatoid arthritis despite receiving methotrexate.

    METHODS: In an ...

    Also Ranks for: Methotrexate Patients |  rheumatoid arthritis |  30 weeks |  α monoclonal antibody |  necrosis factor

    Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial


    [ PUBLICATION ]
    KOL Index score: 18907

    BACKGROUND: Roughly a third of patients with rheumatoid arthritis treated with biological treatments receive them as monotherapy. Tocilizumab--an inhibitor of interleukin 6 receptor signalling--has been studied as monotherapy in several clinical trials. We assessed the efficacy and safety of tocilizumab monotherapy compared with adalimumab monotherapy for patients with rheumatoid arthritis.

    METHODS: We did this randomised, double-blind, parallel-group, phase 4 superiority study in 76 ...

    Also Ranks for: Adalimumab Monotherapy |  rheumatoid arthritis |  patients tocilizumab |  baseline das28 |  phase 4

    Secukinumab, an Interleukin-17A Inhibitor, in Ankylosing Spondylitis


    [ PUBLICATION ]
    KOL Index score: 17791

    BACKGROUND: Secukinumab is an anti-interleukin-17A monoclonal antibody that has been shown to control the symptoms of ankylosing spondylitis in a phase 2 trial. We conducted two phase 3 trials of secukinumab in patients with active ankylosing spondylitis.

    METHODS: In two double-blind trials, we randomly assigned patients to receive secukinumab or placebo. In MEASURE 1, a total of 371 patients received intravenous secukinumab (10 mg per kilogram of body weight) or matched placebo at weeks ...

    Also Ranks for: Ankylosing Spondylitis |  secukinumab patients |  150 75 |  week measure |  monoclonal antibodies

    Predictors of joint damage in patients with early rheumatoid arthritis treated with high‐dose methotrexate with or without concomitant infliximab: Results from the ASPIRE trial


    [ PUBLICATION ]
    KOL Index score: 17615

    OBJECTIVE: To identify disease characteristics leading to progression of joint damage in patients with early rheumatoid arthritis (RA) treated with methotrexate (MTX) versus those treated with infliximab plus MTX.

    METHODS: Patients who had not previously been treated with MTX with active RA were randomly assigned to receive escalating doses of MTX up to 20 mg/week plus placebo or infliximab at weeks 0, 2, and 6, and every 8 weeks thereafter through week 46. Radiographic joint damage was ...

    Also Ranks for: Joint Damage |  mtx infliximab |  early rheumatoid arthritis |  radiographic progression patients |  baseline week

    Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour ne


    [ PUBLICATION ]
    KOL Index score: 17338

    OBJECTIVE: To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab.

    METHODS: Patients (n = 1049) with active RA for 3 years or less and no previous methotrexate treatment were randomly assigned (4 : 5 : 5) to receive methotrexate plus placebo or methotrexate plus infliximab 3 or 6 mg/kg at weeks 0, 2 and 6, and every 8 weeks thereafter to week 46. Disease activity ...

    Also Ranks for: Methotrexate Monotherapy |  disease activity states |  radiographic progression patients |  rheumatoid arthritis |  necrosis factor

    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, do


    [ PUBLICATION ]
    KOL Index score: 17302

    OBJECTIVE: To evaluate the efficacy and safety of 2 dosage regimens of lyophilized certolizumab pegol (a novel PEGylated anti-tumor necrosis factor agent) as adjunctive therapy to methotrexate (MTX) in patients with active rheumatoid arthritis (RA) with an inadequate response to MTX therapy alone.

    METHODS: In this 52-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial, 982 patients were randomized 2:2:1 to receive treatment with subcutaneous ...

    Also Ranks for: Certolizumab Pegol |  active rheumatoid arthritis |  placebo mtx |  physical function |  phase iii

    Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate‐naive patients with active rheumatoid arthritis: Twenty‐four–week results


    [ PUBLICATION ]
    KOL Index score: 17186

    OBJECTIVE: To assess the safety and efficacy of golimumab in methotrexate (MTX)-naive patients with active rheumatoid arthritis (RA).

    METHODS: MTX-naive patients with RA (n = 637) were randomized to receive placebo plus MTX (group 1), golimumab 100 mg plus placebo (group 2), golimumab 50 mg plus MTX (group 3), or golimumab 100 mg plus MTX (group 4). Subcutaneous injections of golimumab or placebo were administered every 4 weeks. The dosage of MTX/placebo capsules started at 10 mg/week ...

    Also Ranks for: Golimumab Mtx |  acr50 response |  rheumatoid arthritis |  nonsteroidal antibodies |  primary point

    Golimumab, a Human Anti–Tumor Necrosis Factor Monoclonal Antibody, Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Yea


    [ PUBLICATION ]
    KOL Index score: 16699

    OBJECTIVE: To assess 2-year golimumab efficacy/safety in patients with active rheumatoid arthritis (RA) who had never taken methotrexate (MTX).

    METHODS: RA patients who had never taken MTX (n = 637) were randomized (1:1:1:1) to placebo + MTX (group 1), golimumab 100 mg + placebo (group 2), golimumab 50 mg + MTX (group 3), or golimumab 100 mg + MTX (group 4) every 4 weeks. Nonresponders based on week 28 swollen/tender joint counts changed treatment as follows: group 1 added golimumab 50 ...

    Also Ranks for: Golimumab Mtx |  active rheumatoid arthritis |  phase iii |  physical function |  necrosis factor

    A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-ass


    [ PUBLICATION ]
    KOL Index score: 16370

    OBJECTIVES: To compare efficacy and safety of ixekizumab (IXE) to adalimumab (ADA) in biological disease-modifying antirheumatic drug-naïve patients with both active psoriatic arthritis (PsA) and skin disease and inadequate response to conventional synthetic disease-modifying antirheumatic drug (csDMARDs).

    METHODS: Patients with active PsA were randomised (1:1) to approved dosing of IXE or ADA in an open-label, head-to-head, blinded assessor clinical trial. The primary objective was to ...

    Also Ranks for: Active Psoriatic Arthritis |  patients psa |  efficacy safety |  pasi100 response |  ixekizumab adalimumab

     

    Paul Emery: Influence Statistics

    Open the FULL List in Excel
    Sample of concepts for which Paul Emery is among the top experts in the world.
    Concept World rank
    vegf vascular pattern #1
    das4424 #1
    therapy switching #1
    new immunological target #1
    sulfasalazine conservative therapy #1
    empire trial #1
    treatment ctla4ig #1
    remission combination #1
    cell biomarkers relapse #1
    wk 52 #1
    complete depletion cycle #1
    2 weeks tocilizumab #1
    marginal erosions #1
    chapter 10i rituximab #1
    radiographic progression adalimumab #1
    enriching case selection #1
    patients low igg #1
    longterm extension patients #1
    irc rheumatoid arthritis #1
    firstcycle nonresponders cycle #1
    spa rls #1
    traf1 c5 association #1
    placebo mtx therapy #1
    synovitis bone damage #1
    mtx proportion #1
    smoking csa onset #1
    retreatment rtx #1
    cd45⁻ #1
    vascular phenotype psoriasis #1
    xray progression #1
    ldi lclasi #1
    depletion clinical #1
    mtx inadequate responders #1
    etnmtx etn #1
    undifferentiated inflammatory #1
    musculoskeletal sle #1
    acr50 response week #1
    patients cd16 granulocytes #1
    fatigue medications #1
    axial spondyloarthritis classification #1
    sarilumab tocilizumab #1
    n3732 #1
    naïve cell #1
    mus training rheumatologists #1
    acpa positive individuals #1
    major therapeutic advance #1
    rheumatologist ultrasonographers #1
    combination therapy methotrexate #1
    agents arthritis #1
    rituximab clinical response #1
    Open the FULL List in Excel

    Key People For Rheumatoid Arthritis

    Top KOLs in the world
    #1
    Paul Emery
    rheumatoid arthritis ankylosing spondylitis radiographic progression
    #2
    Josef Sebastian Smolen
    rheumatoid arthritis systemic lupus erythematosus radiographic progression
    #3
    James F Fries
    rheumatoid arthritis physical function systemic lupus erythematosus
    #4
    John Turner Sharp
    rheumatoid arthritis radiographic progression joint space width
    #5
    Frederick J Wolfe
    rheumatoid arthritis work disability rheumatic diseases
    #6
    Matthew H Liang
    rheumatoid arthritis systemic lupus erythematosus lyme disease
    Select a search phrase   rheumatoid arthritis , rheumatoid arthritis patients , rheumatoid arthritis treatment , rheumatoid arthritis risk , rheumatoid arthritis study

    Paul Emery:Expert Impact

    Concepts for whichPaul Emeryhas direct influence:Rheumatoid arthritis,  Psoriatic arthritis,  Patients rheumatoid arthritis,  Ankylosing spondylitis,  Arthritis rheumatoid,  Early rheumatoid arthritis,  Radiographic progression,  Inflammatory arthritis.

    Paul Emery:KOL impact

    Concepts related to the work of other authors for whichfor which Paul Emery has influence:Rheumatoid arthritis,  Ankylosing spondylitis,  Autoimmune diseases,  Systemic sclerosis,  Necrosis factor,  Monoclonal antibodies,  Stem cells.


     

    Tools

    Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


    National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom | Rheumatology, Leeds Teaching Hospitals NHS Trust, Chapel Allerton Hospital, Leeds LS7 4SA, UK. | Leeds Institu

    Copied to clipboard!

KOLs  Ranked Lists of Experts
Therapeutic areas
  • Certain infectious and parasitic diseasesInfectious and parasitic
  • NeoplasmsNeoplasms
  • Endocrine, nutritional and metabolic diseasesEndocrine, nutritional and metabolic
  • Diseases of the nervous systemDiseases of the nervous system
  • Diseases of the eye and adnexaDiseases of the eye and adnexa
  • Diseases of the digestive systemDiseases of the digestive system
  • Diseases of the skin and subcutaneous tissueDiseases of the skin and subcutaneous tissue
  • Diseases of the genitourinary systemDiseases of the genitourinary system
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classifiedSymptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
  • External causes of morbidity and mortalityExternal causes of morbidity and mortality
  • Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismDiseases of the blood and blood-forming organs
  • Mental and behavioural disordersMental and behavioural disorders
  • Diseases of the ear and mastoid processDiseases of the ear and mastoid process
  • Diseases of the circulatory systemDiseases of the circulatory system
  • Diseases of the respiratory systemDiseases of the respiratory system
  • Diseases of the musculoskeletal system and connective tissueDiseases of the musculoskeletal system and connective tissue
  • Pregnancy, childbirth and the puerperiumPregnancy, childbirth and the puerperium
  • Certain conditions originating in the perinatal periodCertain conditions originating in the perinatal period
  • Congenital malformations, deformations and chromosomal abnormalitiesCongenital malformations, deformations and chromosomal abnormalities
  • Injury, poisoning and certain other consequences of external causesInjury, poisoning and certain other consequences of external causes
  • Factors influencing health status and contact with health servicesFactors influencing health status and contact with health services
  • Codes for special purposesCodes for special purposes
About KOL
  • About KOL
  • Learn more about our technology and how more and more universities, research organizations, and companies in all industries are using our data to lower their costs.
  • Why KOL?
  • Tutorials
  • KOL Jobs
  • KOL News
  • KOL Events
  • Become a Partner
  • Contact Us
  • Site Map
KOL New YorkKOL London
search KOL Search
search KOL Search
KOLs Data Cloud
  1. smart_toy
  2. KOL Guides arrow_forward
  3. Medical conferences arrow_forward
  4. KOLs #1 arrow_forward
  5. By Country arrow_forward
  6. Certain infectious and parasitic diseasesInfectious and parasitic
  7. NeoplasmsNeoplasms
  8. Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanismDiseases of the blood and blood-forming organs
  9. Endocrine, nutritional and metabolic diseasesEndocrine, nutritional and metabolic diseases
  10. Mental and behavioural disordersMental and behavioural disorders
  11. Diseases of the nervous systemDiseases of the nervous system
  12. Diseases of the eye and adnexaDiseases of the eye and adnexa
  13. Diseases of the ear and mastoid processDiseases of the ear and mastoid process
  14. Diseases of the circulatory systemDiseases of the circulatory system
  15. Diseases of the respiratory systemDiseases of the respiratory system
  16. Diseases of the digestive systemDiseases of the digestive system
  17. Diseases of the skin and subcutaneous tissueDiseases of the skin and subcutaneous tissue
  18. Diseases of the musculoskeletal system and connective tissueDiseases of the musculoskeletal system and connective tissue
  19. Diseases of the genitourinary systemDiseases of the genitourinary system
  20. Pregnancy, childbirth and the puerperiumPregnancy, childbirth and the puerperium
  21. Certain conditions originating in the perinatal periodCertain conditions originating in the perinatal period
  22. Congenital malformations, deformations and chromosomal abnormalitiesCongenital malformations, deformations and chromosomal abnormalities
  23. Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classifiedSymptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
  24. Injury, poisoning and certain other consequences of external causesInjury, poisoning and certain other consequences of external causes
  25. External causes of morbidity and mortalityExternal causes of morbidity and mortality
  26. Factors influencing health status and contact with health servicesFactors influencing health status and contact with health services
  27. Codes for special purposesCodes for special purposes
  28. About KOL arrow_forward
  29. Contact Us
    • KOL in English   
    • Deutsch   
    • Français   
    • Español   
    • 中国人   
    • 日本   
    • हिंदी   
    • Português   
    • Indo   
    • Norsk   
  1. Consult the KOL Community Resources
  2. High-quality guides curated by a team of professionals observing a rigorous review process.

    Our Health Guides highlight the work of the #1 KOLs for each Therapeutic Area.
  3. ADD/ADHD
    Stephen V Faraone - KOL #1 AdhdStephen V Faraone
    KOL #1 for Adhd
  4. Allergic conjunctivitis
    Mark B Abelson - KOL #1 Allergic ConjunctivitisMark B Abelson
    KOL #1 for Allergic Conjunctivitis
  5. Allergies
    Erika RM von Mutius - KOL #1 AllergiesErika RM von Mutius
    KOL #1 for Allergies
  6. Arthritis
    Rikard Holmdahl - KOL #1 ArthritisRikard Holmdahl
    KOL #1 for Arthritis
  7. Atrial fibrillation
    Gregory Yoke Hong Lip - KOL #1 Atrial FibrillationGregory Yoke Hong Lip
    KOL #1 for Atrial Fibrillation
  8. Babesiosis
    Peter J Krause - KOL #1 BabesiosisPeter J Krause
    KOL #1 for Babesiosis
  9. Breast Cancer
    Steven Alexander Narod - KOL #1 Breast CancerSteven Alexander Narod
    KOL #1 for Breast Cancer
  10. Cancer
    Anne Marie Tjønneland - KOL #1 CancerAnne Marie Tjønneland
    KOL #1 for Cancer
  11. DVT
    Harry Roger Büller - KOL #1 Deep Vein ThrombosisHarry Roger Büller
    KOL #1 for Deep Vein Thrombosis
  12. Encephalopathy
    Roger F Butterworth - KOL #1 EncephalopathyRoger F Butterworth
    KOL #1 for Encephalopathy
  13. Flea bites
    Bernard Joseph Hinnebusch - KOL #1 Flea BitesBernard Joseph Hinnebusch
    KOL #1 for Flea Bites
  14. Hemiparesis
    Jean‐Michel Gracies - KOL #1 HemiparesisJean‐Michel Gracies
    KOL #1 for Hemiparesis
  15. Nasal Vestibulitis
    Mario E Lacouture - KOL #1 Nasal VestibulitisMario E Lacouture
    KOL #1 for Nasal Vestibulitis
  16. See More ...
  1. About KOL
  2. Learn more about our technology and how more and more universities, research organizations, and companies in all industries are using our data to lower their costs.
  3. Why KOL?
  4. Tutorials
  5. KOL Jobs
  6. KOL News
  7. KOL Events
  8. Become a Partner
  9. Contact Us
  10. Site Map
  • Pfizer
  • Johnson & Johnson
  • Roche
  • Havas
  • AbbVie
  • Bristol Myers Squibb
  • Sanofi
  • Canada
  • France
  • Germany
  • India
  • Taiwan
  • Türkiye
  • United Kingdom (UK)
  • United States

  • Products and pricing

    • KOL Marketing Cloud pricing
    • Site Map
  • KOLs Engage

    • Contact sales
    • Become a Partner
  • Privacy

    • Privacy policy
    • Acceptable use policy
  • Local KOLs

    • KOL NYC
    • KOL Chicago IL
    • KOL Boston MA

Copyright © 2023 - Key Opinion Leaders (KOL).

KOL does not provide healthcare advice, medical diagnosis or treatment.

KOL
641 Avenue of the America's
New York, NY 10011
United States of America
KOL
2400 SE Washington Blvd.
Bartlesville, OK 74006
United States of America